Immunoexpression of RANK, RANKL and OPG in sporadic odontogenic keratocysts and their potential association with recurrence

Kisielowski, Konrad; Drozdzowska, Bogna; Koszowski, Rafał; Rynkiewicz, Magdalena; Szuta, Mariusz; Rahnama-Hezavah, Mansur; Babiuch, Karolina; Tyrakowski, Michał; Bednarczyk, Anna; Kaczmarzyk, Tomasz

doi:10.17219/acem/130907

Cited by 1 publication

(5 citation statements)

References 26 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we are not certain whether it has any prognostic relevance. First, our previous 18 and current results do not show that the expression of RANK, RANKL or OPG, or RANKL/OPG balance in sporadic OKCs has any influence on the risk and time to recurrence in the survival model. It was also not possible to calculate the HR for syndromic cases in this regard.…”

Section: Discussioncontrasting

confidence: 72%

“…[49][50][51] In our previous report, we showed that the majority of sporadic OKCs exhibited a RANKL > OPG ratio or, to a lesser degree, a RANKL = OPG ratio. 18 In the current study, we showed that there is a significantly increased expression of RANKL in recurrent syndromic lesions. In fact, 80% of the recurrent syndromic OKCs exhibited a strong reaction to RANKL, and 60% of the recurrent syndromic OKCs had a RANKL > OPG ratio.…”

Section: Discussionsupporting

confidence: 55%

“…27,47 In short, binding of RANKL to RANK leads to proosteoclast recruitment, and osteoclast activation and survival, whereas OPG is a decoy receptor for RANKL that blocks osteoclast formation by inhibiting RANKL from binding to RANK. 18,27,48 Not surprisingly, the vast majority of lesions in the current series exhibited RANKL > OPG or, to a lesser extent, a RANKL = OPG ratio, irrespective of the association with NBCCS. Many previous studies have demonstrated an elevated expression of RANKL in comparison with OPG in various osteolytic diseases, including aggressive odontogenic tumors like ameloblastoma, odontogenic myxoma and ameloblastic fibroma.…”

Section: Discussionmentioning

confidence: 53%

“…To evaluate the potential clinicoradiological, histopathological and immunohistochemical prognostic factors, we employed the methods used in our previous studies. 17,18 At the time of diagnosis, panoramic and occlusal radiographs were taken, supplemented in most cases with computed tomography (CT). Follow-up appointments took place quarterly in the 1 st postoperative year, and semiannually starting from the 2 nd postoperative year.…”

Section: Study Design and Patientsmentioning

confidence: 99%

“…We did not, however, reveal any prognostic significance of immunoexpression of Bcl-2, cyclin D1, p53, osteoprotegerin (OPG), PCNA, receptor activator of nuclear factor κ B (RANK), and receptor activator of nuclear factor κ B ligand (RANKL) for OKCs not associated with NBCCS. 17,18 Hitherto, little is known about whether clinicoradiological and pathological features or expression of immunohistochemical markers are also associated with recurrence in cases of syndromic OKCs.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Prognostic relevance of clinicopathological factors in sporadic and syndromic odontogenic keratocysts: A comparative study

Kisielowski¹,

Drozdzowska²,

Szuta³

et al. 2022

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Current evidence suggests that nevoid basal cell carcinoma syndrome (NBCCS)-associated odontogenic keratocysts (OKCs) exhibit more aggressive clinical behavior and a higher tendency to relapse. The prognostic efficacy of various markers in sporadic and syndromic OKCs is unclear, and so are the results of studies on the usefulness of immunohistochemistry in distinguishing syndromic from sporadic OKCs.Objectives. This retrospective study aimed to compare the prognostic relevance of various clinicoradiological and histopathological features, as well as the immunoexpression of COX-2, Bcl-2, proliferating cell nuclear antigen (PCNA), p53, Ki-67, osteoprotegerin (OPG), receptor activator of nuclear factor κ B (RANK) and receptor activator of nuclear factor κ B ligand (RANKL), as well as RANKL/OPG balance between sporadic and syndromic OKCs, and to test their utility in distinguishing the 2 types of OKC. Materials and methods.We compared the immunoexpression of the aforementioned markers between 31 sporadic and 12 syndromic OKCs, and tested clinicopathological findings and levels of immunostaining against recurrence.Results. We found a significant association between NBCCS and OKC recurrence. There were significant differences in PCNA, p53 and OPG immunoexpression between sporadic and syndromic OKCs. We also found that recurrent sporadic OKCs were significantly larger and markedly more often associated with cortical perforation. Recurrent sporadic OKCs exhibited COX-2 upregulation, but we failed to demonstrate its prognostic relevance. Recurrent syndromic OKCs showed a markedly higher RANKL > OPG ratio. Conclusions.The NBCCS-associated OKCs are significantly more prone to recur than their sporadic counterparts. Larger size and radiological signs of cortical perforation in sporadic OKCs may indicate a higher risk of recurrence. The COX-2 is upregulated in recurrent sporadic OKCs, whereas recurrent syndromic OKCs exhibit higher RANKL and lower OPG expression; however, these findings have no prognostic relevance. The immunoexpression of p53, PCNA and OPG may help to distinguish syndromic from sporadic OKCs.

show abstract

Section: Discussioncontrasting

confidence: 72%